News

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Hims & Hers Health and Novo Nordisk announced a partnership a few months ago, and it has already come to an end. Novo Nordisk ...
While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...
Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...
Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...
Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...
Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...
Under the deal, cash-paying patients can access a month's supply of Wegovy through the Danish drugmaker's Novocare pharmacy ...